scholarly journals Inhibition of cancer cell proliferation by midazolam by targeting transient receptor potential melastatin 7

2013 ◽  
Vol 5 (3) ◽  
pp. 1010-1016 ◽  
Author(s):  
YUNLING DOU ◽  
YUAN LI ◽  
JINGKAO CHEN ◽  
SIHAN WU ◽  
XIAO XIAO ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Cancer Cell ◽  
Transient Receptor Potential ◽  
Receptor Potential ◽  
Cancer Cell Proliferation ◽  
Transient Receptor Potential Melastatin ◽  
Transient Receptor

scholarly journals The Role of Transient Receptor Potential Melastatin 7 (TRPM7) in Cell Viability: A Potential Target to Suppress Breast Cancer Cell Cycle

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 131 ◽  
Author(s):  
Hengrui Liu ◽  
James P. Dilger ◽  
Jun Lin
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Divalent Cation ◽  
Breast Cancer Cells ◽  
Transient Receptor Potential ◽  
Receptor Potential ◽  
Transient Receptor Potential Melastatin ◽  
Transient Receptor

The divalent cation-selective channel transient receptor potential melastatin 7 (TRPM7) channel was shown to affect the proliferation of some types of cancer cell. However, the function of TRPM7 in the viability of breast cancer cells remains unclear. Here we show that TRPM inhibitors suppressed the viability of TRPM7-expressing breast cancer cells. We first demonstrated that the TRPM7 inhibitors 2-aminoethyl diphenylborinate (2-APB), ginsenoside Rd (Gin Rd), and waixenicin A preferentially suppressed the viability of human embryonic kidney HEK293 overexpressing TRPM7 (HEK-M7) cells over wildtype HEK293 (WT-HEK). Next, we confirmed the effects of 2-APB on the TRPM7 channel functions by whole-cell currents and divalent cation influx. The inhibition of the viability of HEK-M7 cells by 2-APB was not mediated by the increase in cell death but by the interruption of the cell cycle. Similar to HEK-M7 cells, the viability of TRPM7-expressing human breast cancer MDA-MB-231, AU565, and T47D cells were also suppressed by 2-APB by arresting the cell cycle in the S phase. Furthermore, in a novel TRPM7 knock-out MDA-MB-231 (KO-231) cell line, decreased divalent influx and reduced proliferation were observed compared to the wildtype MDA-MB-231 cells. 2-APB and Gin Rd preferentially suppressed the viability of wildtype MDA-MB-231 cells over KO-231 by affecting the cell cycle in wildtype but not KO-231 cells. Our results suggest that TRPM7 regulates the cell cycle of breast cancers and is a potential therapeutic target.

scholarly journals The Transient Receptor Potential Melastatin 7 Channel Regulates Pancreatic Cancer Cell Invasion through the Hsp90α/uPA/MMP2 pathway

Neoplasia ◽  
2017 ◽  
Vol 19 (4) ◽  
pp. 288-300 ◽  
Author(s):  
Pierre Rybarczyk ◽  
Alison Vanlaeys ◽  
Bertrand Brassart ◽  
Isabelle Dhennin-Duthille ◽  
Denis Chatelain ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cell ◽  
Cell Invasion ◽  
Transient Receptor Potential ◽  
Pancreatic Cancer Cell ◽  
Receptor Potential ◽  
Cancer Cell Invasion ◽  
Transient Receptor Potential Melastatin ◽  
Transient Receptor

scholarly journals Therapeutic potential of TRPM8 antagonists in prostate cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Marzia Di Donato ◽  
Carmine Ostacolo ◽  
Pia Giovannelli ◽  
Veronica Di Sarno ◽  
Isabel M. Gomez Monterrey ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Transient Receptor Potential ◽  
Prostate Cancer Cell ◽  
Receptor Potential ◽  
Prostate Cancer Cells ◽  
Transient Receptor Potential Melastatin ◽  
Transient Receptor

AbstractTransient receptor potential melastatin-8 (TRPM8) represents an emerging target in prostate cancer, although its mechanism of action remains unclear. Here, we have characterized and investigated the effects of TRPM8 modulators in prostate cancer aggressiveness disclosing the molecular mechanism underlying their biological activity. Patch-clamp and calcium fluorometric assays were used to characterize the synthesized compounds. Androgen-stimulated prostate cancer-derived cells were challenged with the compounds and the DNA synthesis was investigated in a preliminary screening. The most effective compounds were then employed to inhibit the pro-metastatic behavior of in various PC-derived cells, at different degree of malignancy. The effect of the compounds was then assayed in prostate cancer cell-derived 3D model and the molecular targets of selected compounds were lastly identified using transcriptional and non-transcriptional reporter assays. TRPM8 antagonists inhibit the androgen-dependent prostate cancer cell proliferation, migration and invasiveness. They are highly effective in reverting the androgen-induced increase in prostate cancer cell spheroid size. The compounds also revert the proliferation of castrate-resistant prostate cancer cells, provided they express the androgen receptor. In contrast, no effects were recorded in prostate cancer cells devoid of the receptor. Selected antagonists interfere in non-genomic androgen action and abolish the androgen-induced androgen receptor/TRPM8 complex assembly as well as the increase in intracellular calcium levels in prostate cancer cells. Our results shed light in the processes controlling prostate cancer progression and make the transient receptor potential melastatin-8 as a ‘druggable’ target in the androgen receptor-expressing prostate cancers.

Sign in / Sign up

Export Citation Format

Share Document